Comparison of the immunogenicity of Cervarix^® and Gardasil^® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults

References

• Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244 - 65; http://dx.doi.org/10.1136/jcp.55.4.244; PMID: 11919208
   PubMed Web of Science ®Google Scholar
• Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24 Suppl 3:S3/1-10.
   Google Scholar
• Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370:890 - 907; http://dx.doi.org/10.1016/S0140-6736(07)61416-0; PMID: 17826171
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12 - 9; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F; PMID: 10451482
   PubMed Web of Science ®Google Scholar
• Barr E, Tamms G. Quadrivalent human papillomavirus vaccine. Clin Infect Dis 2007; 45:609 - 7; http://dx.doi.org/10.1086/520654; PMID: 17682997
   PubMed Web of Science ®Google Scholar
• Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. [Cervarix] Drugs 2008; 68:359 - 72; http://dx.doi.org/10.2165/00003495-200868030-00007; PMID: 18257611
   PubMed Web of Science ®Google Scholar
• Monie A, Hung CF, Roden R, Wu TC. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2008; 2:97 - 105; PMID: 19707432
   PubMedGoogle Scholar
• Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 2006; 66:1263 - 71, discussion 1272-3; http://dx.doi.org/10.2165/00003495-200666090-00008; PMID: 16827602
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al, Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048 - 56; http://dx.doi.org/10.1016/S1470-2045(10)70230-8; PMID: 20952254
   PubMed Web of Science ®Google Scholar
• Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781 - 9; http://dx.doi.org/10.1016/S1473-3099(12)70187-1; PMID: 22920953
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, et al, HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:100 - 10; http://dx.doi.org/10.1016/S1470-2045(11)70287-X; PMID: 22075170
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al, HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301 - 14; http://dx.doi.org/10.1016/S0140-6736(09)61248-4; PMID: 19586656
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199:936 - 44; http://dx.doi.org/10.1086/597309; PMID: 19236277
   PubMed Web of Science ®Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926 - 35; http://dx.doi.org/10.1086/597307; PMID: 19236279
   PubMed Web of Science ®Google Scholar
• Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, et al. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Hum Vaccin Immunother 2013; 9:1399 - 406; http://dx.doi.org/10.4161/hv.24340; PMID: 23571174
   PubMed Web of Science ®Google Scholar
• Hagensee ME, Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci 2004; 328:57 - 63; http://dx.doi.org/10.1097/00000441-200407000-00008; PMID: 15254442
   PubMed Web of Science ®Google Scholar
• Gormley RH, Kovarik CL. Dermatologic manifestations of HPV in HIV-infected individuals. Curr HIV/AIDS Rep 2009; 6:130 - 8; http://dx.doi.org/10.1007/s11904-009-0018-8; PMID: 19589298
   PubMedGoogle Scholar
• De Panfilis G, Melzani G, Mori G, Ghidini A, Graifemberghi S. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. Sex Transm Dis 2002; 29:121 - 5; http://dx.doi.org/10.1097/00007435-200203000-00001; PMID: 11875372
   PubMed Web of Science ®Google Scholar
• Sunesen KG, Nørgaard M, Thorlacius-Ussing O, Laurberg S. Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. Int J Cancer 2010; 127:675 - 84; http://dx.doi.org/10.1002/ijc.25080; PMID: 19960431
   PubMed Web of Science ®Google Scholar
• Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59 - 67; http://dx.doi.org/10.1016/S0140-6736(07)61050-2; PMID: 17617273
   PubMed Web of Science ®Google Scholar
• Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT, Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728 - 36; http://dx.doi.org/10.7326/0003-4819-148-10-200805200-00005; PMID: 18490686
   PubMed Web of Science ®Google Scholar
• Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Mary-Krause M, FHDH-ANRS CO 4. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22:1203 - 11; http://dx.doi.org/10.1097/QAD.0b013e3283023f78; PMID: 18525266
   PubMed Web of Science ®Google Scholar
• Jessica A.. Kahn, Jiahong Xu, Bill G. Kapogiannis, Bret Rudy, René Gonin, Nancy Liu, et al. Immunogenicity and Safety of the Human Papillomavirus-6, -11, -16, -18 Vaccine in HIV-Infected Young Women. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2013;
   Web of Science ®Google Scholar
• Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS, Handelsman EL, Nowak B, Sattler CA, Saah A, et al, IMPAACT P1047 Protocol Team. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010; 55:197 - 204; http://dx.doi.org/10.1097/QAI.0b013e3181de8d26; PMID: 20574412
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Lebacq M, van der Most R, et al, HPV-010 Study Group. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011; 7:1359 - 73; http://dx.doi.org/10.4161/hv.7.12.18282; PMID: 22048172
   PubMed Web of Science ®Google Scholar
• Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202:1246 - 53; http://dx.doi.org/10.1086/656320; PMID: 20812850
   PubMed Web of Science ®Google Scholar
• Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, Durand C, Hervé C, Descamps D. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine 2013; 31:5745 - 53; http://dx.doi.org/10.1016/j.vaccine.2013.09.032; PMID: 24091311
   PubMed Web of Science ®Google Scholar
• Toft L, Storgaard M, Müller M, Sehr P, Bonde J, Tolstrup M, Ostergaard L, Søgaard OS. Comparison of the Immunogenicity and Reactogenicity of Cervarix and Gardasil Human Papillomavirus Vaccines in HIV-Infected Adults: A Randomized, Double-Blind Clinical Trial. J Infect Dis 2013; http://dx.doi.org/10.1093/infdis/jit657; PMID: 24273179
   PubMed Web of Science ®Google Scholar
• Weinberg A, Song LY, Saah A, Brown M, Moscicki AB, Meyer WA 3rd, Bryan J, Levin MJ, IMPAACT/PACTG P1047 Team. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis 2012; 206:1309 - 18; http://dx.doi.org/10.1093/infdis/jis489; PMID: 22859825
   PubMed Web of Science ®Google Scholar
• Sehr P, Rubio I, Seitz H, Putzker K, Ribeiro-Müller L, Pawlita M, Müller M. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One 2013; 8:e75677; http://dx.doi.org/10.1371/journal.pone.0075677; PMID: 24124504
   PubMed Web of Science ®Google Scholar
• Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011; 105:28 - 37; http://dx.doi.org/10.1038/bjc.2011.185; PMID: 21629249
   PubMed Web of Science ®Google Scholar
• Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009; 5:696 - 704; http://dx.doi.org/10.4161/hv.5.10.9515; PMID: 19855170
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr., Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576 - 85; http://dx.doi.org/10.1056/NEJMoa1010971; PMID: 22029979
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr., Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364:401 - 11; http://dx.doi.org/10.1056/NEJMoa0909537; PMID: 21288094
   PubMed Web of Science ®Google Scholar
• Green MS, Shohat T, Lerman Y, Cohen D, Slepon R, Duvdevani P, Varsano N, Dagan R, Mendelson E. Sex differences in the humoral antibody response to live measles vaccine in young adults. Int J Epidemiol 1994; 23:1078 - 81; http://dx.doi.org/10.1093/ije/23.5.1078; PMID: 7860159
   PubMed Web of Science ®Google Scholar
• Klein SL. Sex differences in prophylaxis and therapeutic treatments for viral diseases. Handb Exp Pharmacol 2012; •••:499 - 522; PMID: 23027464
   PubMedGoogle Scholar
• Seitz H, Schmitt M, Böhmer G, Kopp-Schneider A, Müller M. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2. Int J Cancer 2013; 132:E139 - 48; http://dx.doi.org/10.1002/ijc.27831; PMID: 22961598
   PubMedGoogle Scholar
• Castro F, Dirks WG, Fähnrich S, Hotz-Wagenblatt A, Pawlita M, Schmitt M. High-throughput SNP-based authentication of human cell lines. Int J Cancer 2013; 132:308 - 14; http://dx.doi.org/10.1002/ijc.27675; PMID: 22700458
   PubMed Web of Science ®Google Scholar
• Schmitt M, Pawlita M. High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res 2009; 37:e119; http://dx.doi.org/10.1093/nar/gkp581; PMID: 19589807
   PubMedGoogle Scholar